ストックスクリーナーアプリを入手
177.09
0.64%
1.12
アフターアワーズ：
177.09
Becton Dickinson Co (BDX) 最新ニュース
A Big Move By Waters Corporation And Becton, Dickinson And Company (NYSE:WAT) - Seeking Alpha
BD’s biosciences & diagnostics unit in $17.5B merger with Waters - BioWorld MedTech
Becton Dickinson Announces Reverse Morris Trust with Waters - TipRanks
Milford’s Waters Corp. strikes $17.5 billion deal to merge with BD’s diagnostics unit - The Boston Globe
Waters, BD Unite in $17.5B Diagnostics Deal - USA Herald
Waters inks $17.5B merger with division of BD - The Business Journals
Becton Dickinson Spins Off Biosciences In $17.5 Billion Waters Deal - Finimize
Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal - The Wall Street Journal
Waters, BD Biosciences & Diagnostic Solutions to Merge in $17.5B Deal - Medical Product Outsourcing
Here’s Why Becton, Dickinson and Company (BDX) Traded Lower in Q2 - Insider Monkey
Why is Waters Stock Down On Monday?Becton Dickinson (NYSE:BDX), Waters (NYSE:WAT) - Benzinga
Becton Dickinson gets its spinoff deal, but the stock is still falling - MarketWatch
Becton, Dickinson and Company (BDX) Announces Strategic Merger w - GuruFocus
Waters and BD’s Biosciences & Diagnostic Solutions Business To Merge - citybiz
Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing - Placera.se
Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal - MarketScreener
The Best High Yield Medical Device Stock to Invest $1,000 in Right Now - The Motley Fool
Becton, Dickinson and Co. Advances with SiteRite 9 Ultrasound System Study - TipRanks
BD to acquire Bard - The Covington News
BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment - MarketScreener
BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment, Effective July 2 - MarketScreener
Wells Fargo Remains a Hold on Becton Dickinson (BDX) - The Globe and Mail
Becton, Dickinson and Co Completes Key Study on HPV Diagnostic Kit - TipRanks
Becton, Dickinson General Counsel to Be Medtronic Top Lawyer (1) - Bloomberg Law News
Becton, Dickinson and Co’s Latest Study on Male Incontinence Solutions: Market Insights - TipRanks
Becton, Dickinson and Company (BDX): A Bull Case Theory - Insider Monkey
YieldBoost Becton, Dickinson From 2.5% To 15.5% Using Options - Nasdaq
BD upgrades laboratory in Suzhou - China Daily
Investors Can Still File Late Claims in BDX Settlement — Here’s How to Get Your Share - TradingView
Becton Dickinson’s SWOT analysis: medical giant’s stock faces pivotal shift - Investing.com
Becton Dickinson’s SWOT analysis: medical giant’s stock faces pivotal shift By Investing.com - Investing.com India
Becton Dickinson Stock Price, Quotes and Forecasts | NYSE:BDX - Benzinga
Medical technology firm BD looks to bring products to more PHL hospitals - BusinessWorld Online
Becton Dickinson at Goldman Sachs Conference: Strategic Moves Ahead By Investing.com - Investing.com South Africa
Becton Dickinson at Goldman Sachs Conference: Strategic Moves Ahead - Investing.com Australia
Becton, Dickinson And Co To Present At Goldman Sachs Conference; Webcast At 2:00 PM ET - Nasdaq
Stifel maintains Becton Dickinson stock with a $224 target - Investing.com
Here's How You Can Earn $100 In Passive Income By Investing In Becton Dickinson Stock - Yahoo Finance
Barclays Lowers Becton, Dickinson & Co. (BDX) Price Target, Maintains Overweight Rating - MSN
BD’s Future Plans: Shed Life Sciences to Fund Medical Technology - Lab Manager
How Is Becton, Dickinson and Company’s Performance Compared to Other Medical Instruments & Supplies Stocks? - Barchart.com
Becton Dickinson (BDX) Maintains Overweight Rating Despite Price Target Cut | BDX Stock News - GuruFocus
Barclays lowers Becton Dickinson stock price target to $241 By Investing.com - Investing.com South Africa
Barclays Adjusts Price Target on Becton, Dickinson and Company to $241 From $261 - marketscreener.com
Barclays lowers Becton Dickinson stock price target to $241 - Investing.com
Becton Dickinson (BDX) Receives Adjusted Price Target from Barcl - GuruFocus
Becton Dickinson and : BD Vascular Access Management Recognized with Seal of Approval from Infusion Nurses Society - marketscreener.com
Becton Dickinson (BDX) Receives Adjusted Price Target from Barclays | BDX Stock News - GuruFocus
Becton Dickinson EVP David Shan Sells Shares and Other Important Updates - TradingView
Insider Sell: David Shan Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus
BD to Present at Goldman Sachs 46th Annual Global Healthcare Conference - Quantisnow
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - GlobeNewswire
Becton, Dickinson and Company to Initiate Real-World Patient Data Registry for the Rotarex?? Atherectomy System in Treatment of Peripheral Artery Disease - marketscreener.com
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease - Becton Dickinson
Becton Dickinson’s SWOT analysis: stock’s future hangs on life sciences spin-off - Investing.com
Saudi Arabia Research Antibodies Market Report 2025-2030, - GlobeNewswire
Saudi Arabia Research Antibodies Market Report 2025-2030, Competitive Analysis of Cell Signaling Technology, Salima Trading, AJ Jeel Medical & Trading Co, Becton, Dickinson and Co, and Merck - Yahoo Finance
0.18%
大文字化:
|
ボリューム (24 時間):